CD33 and acute myeloid leukemia: A novel radioimmunoconjugate using Lintuzumab, 225Ac-lintuzumab, however, has shown early promise in preliminary phase II data in older AML patients unfit for induction chemotherapy who express CD33 on >25% of blasts [64].